We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics Incorporated's (DGX - Free Report) second-quarter 2022 adjusted earnings per share of $2.36 beat the Zacks Consensus Estimate by 9.8%. Adjusted earnings, however, plunged 25.8% from the year-ago adjusted figure.
Certain one-time expenses, like the ones related to amortization expenses, and certain restructuring and integration charges, as well as gains and losses on investments, were excluded from the quarter’s adjusted figures.
GAAP earnings came in at $1.96 per share, a significant decline from the year-ago reported EPS of $4.96.
Revenues
Reported revenues in the second quarter dropped 3.8% year over year to $2.45 billion. Revenues, however, exceeded the Zacks Consensus Estimate by 7.5%. While the company’s legacy base business saw a year-over-year improvement, COVID-19 testing revenues dropped significantly in the reported quarter.
Quarterly Details
Base Business (excludes COVID-19 testing) revenues were $2.09 billion in the reported quarter, up 2.9% year over year. COVID-19 testing revenues on the other hand plunged 30.5% in the second quarter to $355 million.
Diagnostic information services revenues in the quarter were down 3.6% on a year-over-year basis to $2.38 billion.
Quest Diagnostics Incorporated Price and EPS Surprise
Volumes (measured by the number of requisitions) were down 1.4% year over year in the second quarter (down 2.4% organically). Revenue per requisition dropped 2.6% year over year.
Margins
The cost of services during the reported quarter was $1.61 billion, up 2.9% year over year. The gross margin was 34.3%, reflecting a 430-basis point (bp) contraction from the year-ago figure.
Selling, general and administrative expenses declined 1.6% to $422 million in the quarter under review. Adjusted operating margin of 17.1% represented a 468-bp contraction year over year.
Cash, Capital Structure and Solvency
Quest Diagnostics exited the second quarter of 2022 with cash and cash equivalents of $790 million compared with $712 million at the end of the first quarter. Cumulative net cash provided by operating activities at the end of the second quarter was $882 million compared with $1.19 billion in the year-ago period.
In the second quarter, the company repurchased 1.4 million shares for $200 million. In February 2022, Quest Diagnostics’ board of directors increased the size of its share repurchase program by $1 billion. As of Jun 30, 2022, the company had $1.1 billion available under its existing share repurchase authorization.
Banking on consistent improvement in the company’s Base business, Quest Diagnostics has raised its full-year 2022 guidance.
Full-year net revenues are currently estimated in the range of $9.50-$9.75 billion (compared with the earlier projection of $9.20-$9.50 billion). The Zacks Consensus Estimate for the same is pegged lower at $9.33 billion.
Adjusted EPS is now expected in the range of $9.55-$9.95 (the earlier guided range was $9.00-$9.50). The Zacks Consensus Estimate for the metric is pegged at $9.18.
Our Take
Quest Diagnostics reported better-than-expected second-quarter earnings and revenues. However, on a year-over-year basis, the company reported a decline on both fronts due to lower COVID-19 testing demand. Margin contraction was a downside too.
According to the company, the base business performed well despite the industry-wide softer utilization trends. The company has ramped up investments to accelerate growth in the base business, particularly in the areas of advanced diagnostics and direct-to-consumer testing.
With a bullish expectation for the remainder of 2022, the company raised its full-year guidance.
Zacks Rank
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
Upcoming Earnings
Here are some medical stocks that are due to report soon. These have the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy), or #3 to post an earnings beat this quarter.
Merck has a long-term earnings growth rate of 10.1%. MRK’s earnings yield of 7.93% compares favorably with the industry’s 7.91%.
Alcon Inc. (ALC - Free Report) has an Earnings ESP of +5.07% and a Zacks Rank of #2. Alcon’s long-term expected earnings-growth rate is pegged at 14.3%.
Alcon's long-term earnings growth rate is estimated at 14.3%. ALC’s earnings yield of 3.33% compares with the industry’s (8.43%).
BrainsWay Ltd. (BWAY - Free Report) currently has an Earnings ESP of +33.33% and a Zacks Rank of #2.
BrainsWay’s 2023 earnings growth rate is estimated to be 16.7%. BWAY’s 2023 revenue-growth expectation is pegged at 17.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
Quest Diagnostics Incorporated's (DGX - Free Report) second-quarter 2022 adjusted earnings per share of $2.36 beat the Zacks Consensus Estimate by 9.8%. Adjusted earnings, however, plunged 25.8% from the year-ago adjusted figure.
Certain one-time expenses, like the ones related to amortization expenses, and certain restructuring and integration charges, as well as gains and losses on investments, were excluded from the quarter’s adjusted figures.
GAAP earnings came in at $1.96 per share, a significant decline from the year-ago reported EPS of $4.96.
Revenues
Reported revenues in the second quarter dropped 3.8% year over year to $2.45 billion. Revenues, however, exceeded the Zacks Consensus Estimate by 7.5%. While the company’s legacy base business saw a year-over-year improvement, COVID-19 testing revenues dropped significantly in the reported quarter.
Quarterly Details
Base Business (excludes COVID-19 testing) revenues were $2.09 billion in the reported quarter, up 2.9% year over year. COVID-19 testing revenues on the other hand plunged 30.5% in the second quarter to $355 million.
Diagnostic information services revenues in the quarter were down 3.6% on a year-over-year basis to $2.38 billion.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote
Volumes (measured by the number of requisitions) were down 1.4% year over year in the second quarter (down 2.4% organically). Revenue per requisition dropped 2.6% year over year.
Margins
The cost of services during the reported quarter was $1.61 billion, up 2.9% year over year. The gross margin was 34.3%, reflecting a 430-basis point (bp) contraction from the year-ago figure.
Selling, general and administrative expenses declined 1.6% to $422 million in the quarter under review. Adjusted operating margin of 17.1% represented a 468-bp contraction year over year.
Cash, Capital Structure and Solvency
Quest Diagnostics exited the second quarter of 2022 with cash and cash equivalents of $790 million compared with $712 million at the end of the first quarter. Cumulative net cash provided by operating activities at the end of the second quarter was $882 million compared with $1.19 billion in the year-ago period.
In the second quarter, the company repurchased 1.4 million shares for $200 million. In February 2022, Quest Diagnostics’ board of directors increased the size of its share repurchase program by $1 billion. As of Jun 30, 2022, the company had $1.1 billion available under its existing share repurchase authorization.
The company has a 5-year annualized dividend growth rate of 7.43%.
2022 Guidance Raised
Banking on consistent improvement in the company’s Base business, Quest Diagnostics has raised its full-year 2022 guidance.
Full-year net revenues are currently estimated in the range of $9.50-$9.75 billion (compared with the earlier projection of $9.20-$9.50 billion). The Zacks Consensus Estimate for the same is pegged lower at $9.33 billion.
Adjusted EPS is now expected in the range of $9.55-$9.95 (the earlier guided range was $9.00-$9.50). The Zacks Consensus Estimate for the metric is pegged at $9.18.
Our Take
Quest Diagnostics reported better-than-expected second-quarter earnings and revenues. However, on a year-over-year basis, the company reported a decline on both fronts due to lower COVID-19 testing demand. Margin contraction was a downside too.
According to the company, the base business performed well despite the industry-wide softer utilization trends. The company has ramped up investments to accelerate growth in the base business, particularly in the areas of advanced diagnostics and direct-to-consumer testing.
With a bullish expectation for the remainder of 2022, the company raised its full-year guidance.
Zacks Rank
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
Upcoming Earnings
Here are some medical stocks that are due to report soon. These have the right combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy), or #3 to post an earnings beat this quarter.
Merck & Co., Inc. (MRK - Free Report) has an Earnings ESP of +7.18% and a Zacks Rank of #1. The company will release second-quarter 2022 results on Jul 28. You can see the complete list of today’s Zacks #1 Rank stocks here.
Merck has a long-term earnings growth rate of 10.1%. MRK’s earnings yield of 7.93% compares favorably with the industry’s 7.91%.
Alcon Inc. (ALC - Free Report) has an Earnings ESP of +5.07% and a Zacks Rank of #2. Alcon’s long-term expected earnings-growth rate is pegged at 14.3%.
Alcon's long-term earnings growth rate is estimated at 14.3%. ALC’s earnings yield of 3.33% compares with the industry’s (8.43%).
BrainsWay Ltd. (BWAY - Free Report) currently has an Earnings ESP of +33.33% and a Zacks Rank of #2.
BrainsWay’s 2023 earnings growth rate is estimated to be 16.7%. BWAY’s 2023 revenue-growth expectation is pegged at 17.1%.